MG
BMRN icon

Meditor Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Meditor Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-55,100
Closed -$3.98M – 6
2013
Q3 		$3.98M Buy
+55,100
New +$3.66M 0.56% 26

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Meditor Group's BMRN Position: Q4 2013 in Review

Meditor Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2013, closing a stake of 55,100 shares — an estimated $3.98M sold.

Meditor Group first reported a position in BMRN in Q3 2013 and held it in 1 quarter. The position peaked at $3.98M in Q3 2013. 306 funds tracked by Wall St. Rank hold BMRN as of Q4 2013.

  • Meditor Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Meditor Group sold 55,100 BioMarin Pharmaceuticals shares in Q4 2013, an estimated $3.98M.
  • Meditor Group first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Meditor Group's BioMarin Pharmaceuticals position peaked at $3.98M in Q3 2013.
  • 306 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2013.

Based on Meditor Group's 13F filing for Q4 2013, filed 21 Jan 2014.